EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Comparative outcomes of IV Cangrelor and oral P2Y12 inhibitors in ACS patients undergoing revasvularisation: A systematic review and meta-analysis

Venkata Varshitha Bandi, Ahmad Jalil, Fatima Rajab, Karan Manish Bhatt, Amrit Kahlon, Hadia Rajab, Arundhati Sawant, Abdulgafar Dare Ibrahim, Vijay Chennareddy, Odalys Estefania Lara Garcia

Annals of Clinical Cardiology · 02.06.2026

DOI: 10.4103/accj.accj_9_26 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Clinical Cardiology, online erschienen am 02.06.2026. Verfasst von Venkata Varshitha Bandi und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cangrelor is a direct-acting intravenous P2Y12 inhibitor with a rapid onset of action and a short, predictable offset that allows platelet function to return to baseline within an hour of discontinuation. Given these advantages, cangrelor has been increasingly used to decrease the risk of perioperative and procedural complications in acute coronary syndrome (ACS) patients undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).

Objectives

To compare the ischemic and safety outcomes between IV cangrelor and oral P2Y12 inhibitors in patients of ACS undergoing revascularisation.

Methods

A systematic search was conducted of PubMed/MEDLINE, Cochrane Library, ScienceDirect, and ClinicalTrials.gov was conducted from inception to 2024 for randomized clinical trials or observational cohorts comparing IV cangrelor with oral P2Y12 inhibitors among ACS patients undergoing revascularisation. Data was independently reviewed and screened by two reviewers and pooled using a random effects meta-analysis model.

Results

Four studies including 25,881 participants were analyzed. Compared to oral P2Y12 inhibitors, cangrelor demonstrated significantly lower risk of stent thrombosis Across all included studies, patient demographics and baseline risk profiles were similar. Cangrelor was associated with a significantly lower incidence of stent thrombosis (OR 0.56; 95% CI 0.40–0.80; p=0.004) and higher bleeding risk (OR 1.46; 95% CI 1.22–1.74; p

Zitieren

APA

Bandi, V. V., Jalil, A., Rajab, F., Bhatt, K. M., Kahlon, A., Rajab, H., Sawant, A., Ibrahim, A. D., Chennareddy, V., & Garcia, O. E. L. (2026). Comparative outcomes of IV Cangrelor and oral P2Y12 inhibitors in ACS patients undergoing revasvularisation: A systematic review and meta-analysis. Annals of Clinical Cardiology. https://doi.org/10.4103/accj.accj_9_26

Vancouver

Bandi VV, Jalil A, Rajab F, Bhatt KM, Kahlon A, Rajab H, et al. Comparative outcomes of IV Cangrelor and oral P2Y12 inhibitors in ACS patients undergoing revasvularisation: A systematic review and meta-analysis. Annals of Clinical Cardiology. 2026. doi:10.4103/accj.accj_9_26

BibTeX
@article{Bandi2026,
  author = {Bandi, Venkata Varshitha and Jalil, Ahmad and Rajab, Fatima and Bhatt, Karan Manish and Kahlon, Amrit and Rajab, Hadia and Sawant, Arundhati and Ibrahim, Abdulgafar Dare and Chennareddy, Vijay and Garcia, Odalys Estefania Lara},
  title = {Comparative outcomes of IV Cangrelor and oral P2Y12 inhibitors in ACS patients undergoing revasvularisation: A systematic review and meta-analysis},
  journal = {Annals of Clinical Cardiology},
  year = {2026},
  doi = {10.4103/accj.accj_9_26}
}
Kostenlos starten →